PET/CT for Therapy Response Assessment in Lymphoma

被引:160
作者
Hutchings, Martin [1 ,2 ]
Barrington, Sally F. [3 ,4 ]
机构
[1] Copenhagen Univ Hosp, Dept Oncol, Finsen Ctr, Rikshosp, DK-2100 Copenhagen O, Denmark
[2] Copenhagen Univ Hosp, Dept Haematol, Rikshosp, DK-2100 Copenhagen O, Denmark
[3] Kings Coll London, PET Imaging Ctr, London WC2R 2LS, England
[4] Guys & St Thomas Fdn NHS Trust, Div Imaging, London, England
关键词
F-18-FDG; PET; PET/CT; lymphoma; response monitoring; response-adapted therapy; POSITRON-EMISSION-TOMOGRAPHY; NON-HODGKINS-LYMPHOMA; HIGH-DOSE CHEMOTHERAPY; LARGE-CELL LYMPHOMA; INTERIM FDG-PET; PROGNOSTIC VALUE; FOLLOW-UP; INTERNATIONAL WORKSHOP; AGGRESSIVE LYMPHOMA; MALIGNANT-LYMPHOMA;
D O I
10.2967/jnumed.108.057190
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
PET with F-18-FDG is a standard staging procedure for most lymphoma subtypes. Performed during and after therapy for Hodgkin lymphoma (HL) and aggressive non-Hodgkin lymphoma (NHL), F-18-FDG PET results have a high prognostic value and correlate with survival. F-18-FDG PET has been incorporated into revised response criteria for aggressive lymphomas, and several ongoing trials are under way to investigate the value of treatment adaptation based on early F-18-FDG PET results for HL and aggressive NHL. There is little evidence to support the use of F-18-FDG PET for monitoring of the treatment of indolent lymphomas and for routine use in the surveillance setting. So that trial results can be compared and translated easily into clinical practice, uniform and evidence-based guidelines for the interpretation and reporting of response monitoring scans are warranted. Because it is still not proven that the use of interim F-18-FDG PET can improve patient outcomes, we recommend examination of the use of F-18-FDG PET for response monitoring in appropriately designed clinical trials.
引用
收藏
页码:21S / 30S
页数:10
相关论文
共 92 条
[1]  
[Anonymous], STUD 2 ASS RIT CHEM
[2]   CHEMOTHERAPY FOR DIFFUSE LARGE-CELL LYMPHOMA - RAPIDLY RESPONDING PATIENTS HAVE MORE DURABLE REMISSIONS [J].
ARMITAGE, JO ;
WEISENBURGER, DD ;
HUTCHINS, M ;
MORAVEC, DF ;
DOWLING, M ;
SORENSEN, S ;
MAILLIARD, J ;
OKERBLOOM, J ;
JOHNSON, PS ;
HOWE, D ;
BASCOM, GK ;
CASEY, J ;
LINDER, J ;
PURTILO, DT .
JOURNAL OF CLINICAL ONCOLOGY, 1986, 4 (02) :160-164
[3]  
Aviador A, 2007, HAEMATOL-HEMATOL J, V92, P66
[4]  
Bangerter M, 1999, ACTA ONCOL, V38, P799
[5]  
Becherer A, 2003, Q J NUCL MED, V47, P14
[6]   Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation [J].
Becherer, A ;
Mitterbauer, M ;
Jaeger, U ;
Kalhs, P ;
Greinix, HT ;
Karanikas, G ;
Pötzi, C ;
Raderer, M ;
Dudczak, R ;
Kletter, K .
LEUKEMIA, 2002, 16 (02) :260-267
[7]   Predictive value and diagnostic accuracy of F-18-fluoro-deoxy-glucose positron emission tomography treated grade 1 and 2 follicular lymphoma [J].
Bishu, Shrinivas ;
Quigley, Joanna M. ;
Bishu, Shreenath R. ;
Olsasky, Sarah M. ;
Stem, Richard A. ;
Shostrom, Valerie K. ;
Holdeman, Karen P. ;
Paknikar, Subash ;
Armitage, James O. ;
Hankins, Jordan H. .
LEUKEMIA & LYMPHOMA, 2007, 48 (08) :1548-1555
[8]   Hodgkin lymphoma: Response assessment by revised international workshop criteria [J].
Brepoels, Lieselot ;
Stroobants, Sigrid ;
De Wever, Walter ;
Spaepen, Karoline ;
Vandenberghe, Peter ;
Thomas, Jose ;
Uyttebroeck, Anne ;
Mortelmans, Luc ;
De Wolf-Peeters, Christiane ;
Verhoef, Gregor .
LEUKEMIA & LYMPHOMA, 2007, 48 (08) :1539-1547
[9]   Aggressive and indolent non-Hodgkin's lymphoma: Response assessment by integrated international workshop criteria [J].
Brepoels, Lieselot ;
Stroobants, Sigrid ;
De Wever, Walter ;
Spaepen, Karoline ;
Vandenberghe, Peter ;
Thomas, Jose ;
Uyttebroeck, Anne ;
Mortelmans, Luc ;
De Wolf-Peeters, Christiane ;
Verhoef, Gregor .
LEUKEMIA & LYMPHOMA, 2007, 48 (08) :1522-1530
[10]   PET and PET/CT for response evaluation in lymphoma: Current practice and developments [J].
Brepoels, Lieselot ;
Stroobants, Sigrid ;
Verhoef, Gregor .
LEUKEMIA & LYMPHOMA, 2007, 48 (02) :270-282